Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Up 17.1% in October

by · The Cerbat Gem

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Free Report) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 3,980,000 shares, a growth of 17.1% from the September 30th total of 3,400,000 shares. Based on an average trading volume of 596,200 shares, the short-interest ratio is currently 6.7 days. Currently, 7.2% of the shares of the company are short sold.

Institutional Trading of Vanda Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Meeder Asset Management Inc. bought a new position in Vanda Pharmaceuticals in the second quarter worth $39,000. SageView Advisory Group LLC bought a new position in shares of Vanda Pharmaceuticals during the 1st quarter worth about $34,000. ORG Wealth Partners LLC bought a new position in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $40,000. SG Americas Securities LLC bought a new stake in Vanda Pharmaceuticals in the second quarter valued at about $61,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 4,374 shares in the last quarter. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Trading Down 1.9 %

Shares of VNDA stock opened at $4.69 on Wednesday. The firm has a market capitalization of $273.38 million, a P/E ratio of -24.68 and a beta of 0.77. Vanda Pharmaceuticals has a 1 year low of $3.30 and a 1 year high of $6.75. The firm’s fifty day simple moving average is $4.88 and its 200 day simple moving average is $5.23.

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last released its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The company had revenue of $50.47 million during the quarter. Equities research analysts anticipate that Vanda Pharmaceuticals will post -0.49 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the stock. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a report on Thursday, October 24th. They set a “hold” rating on the stock. Cantor Fitzgerald upped their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st.

Check Out Our Latest Report on Vanda Pharmaceuticals

Vanda Pharmaceuticals Company Profile

(Get Free Report)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Read More